CA2694479C - Novel powderous medicaments comprising tiotropium and salmeterol and lactose as carrier - Google Patents
Novel powderous medicaments comprising tiotropium and salmeterol and lactose as carrier Download PDFInfo
- Publication number
- CA2694479C CA2694479C CA2694479A CA2694479A CA2694479C CA 2694479 C CA2694479 C CA 2694479C CA 2694479 A CA2694479 A CA 2694479A CA 2694479 A CA2694479 A CA 2694479A CA 2694479 C CA2694479 C CA 2694479C
- Authority
- CA
- Canada
- Prior art keywords
- lactose
- inhalation
- tiotropium
- salmeterol
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title claims abstract description 75
- 239000003814 drug Substances 0.000 title claims abstract description 68
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title claims abstract description 42
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 title claims description 128
- 239000008101 lactose Substances 0.000 title claims description 128
- 229940110309 tiotropium Drugs 0.000 title claims description 21
- 229960004017 salmeterol Drugs 0.000 title claims description 20
- 229960001375 lactose Drugs 0.000 title description 125
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 title description 123
- 239000000843 powder Substances 0.000 claims abstract description 120
- 238000000034 method Methods 0.000 claims abstract description 73
- 238000002360 preparation method Methods 0.000 claims abstract description 64
- 230000008569 process Effects 0.000 claims abstract description 43
- 229960005018 salmeterol xinafoate Drugs 0.000 claims abstract description 39
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 59
- 239000002245 particle Substances 0.000 claims description 48
- 239000002274 desiccant Substances 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000004806 packaging method and process Methods 0.000 claims description 33
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical group O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000001143 conditioned effect Effects 0.000 claims description 9
- 238000009517 secondary packaging Methods 0.000 claims description 6
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical group C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229960000257 tiotropium bromide Drugs 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 6
- 208000006673 asthma Diseases 0.000 abstract description 4
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 57
- 239000000203 mixture Substances 0.000 description 57
- 239000000470 constituent Substances 0.000 description 47
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 40
- 238000000227 grinding Methods 0.000 description 38
- 239000010408 film Substances 0.000 description 32
- -1 polyethylene Polymers 0.000 description 32
- 229960001021 lactose monohydrate Drugs 0.000 description 31
- 239000004698 Polyethylene Substances 0.000 description 29
- 229920000573 polyethylene Polymers 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 238000002156 mixing Methods 0.000 description 23
- 238000005259 measurement Methods 0.000 description 21
- 230000003750 conditioning effect Effects 0.000 description 20
- 229920003023 plastic Polymers 0.000 description 20
- 239000004033 plastic Substances 0.000 description 20
- 239000007789 gas Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000011049 filling Methods 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 239000004743 Polypropylene Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 229920001155 polypropylene Polymers 0.000 description 9
- 239000004411 aluminium Substances 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 8
- 239000005030 aluminium foil Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000013039 cover film Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000011888 foil Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004952 Polyamide Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229920002647 polyamide Polymers 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- 239000004775 Tyvek Substances 0.000 description 5
- 229920000690 Tyvek Polymers 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 150000002597 lactoses Chemical class 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 239000004800 polyvinyl chloride Substances 0.000 description 5
- 238000009516 primary packaging Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000010457 zeolite Substances 0.000 description 5
- 208000018569 Respiratory Tract disease Diseases 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 239000001307 helium Substances 0.000 description 4
- 229910052734 helium Inorganic materials 0.000 description 4
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 229910021536 Zeolite Inorganic materials 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000012159 carrier gas Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000004920 heat-sealing lacquer Substances 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 238000011022 operating instruction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 238000012982 x-ray structure analysis Methods 0.000 description 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003454 betamimetic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012432 intermediate storage Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/003—Particle size control by passing the aerosol trough sieves or filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007034157 | 2007-07-21 | ||
| DE102007034157.3 | 2007-07-21 | ||
| US5193308P | 2008-05-09 | 2008-05-09 | |
| US61/051,933 | 2008-05-09 | ||
| PCT/EP2008/059465 WO2009013244A1 (de) | 2007-07-21 | 2008-07-18 | Neue pulverförmige arzneimittel enthaltend tiotropium und salmeterol sowie laktose als hilfsstoff |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2694479A1 CA2694479A1 (en) | 2009-01-29 |
| CA2694479C true CA2694479C (en) | 2016-09-13 |
Family
ID=39869109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2694479A Expired - Fee Related CA2694479C (en) | 2007-07-21 | 2008-07-18 | Novel powderous medicaments comprising tiotropium and salmeterol and lactose as carrier |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100189780A1 (enExample) |
| EP (1) | EP2182933B1 (enExample) |
| JP (1) | JP2011509919A (enExample) |
| AR (1) | AR067639A1 (enExample) |
| CA (1) | CA2694479C (enExample) |
| PE (1) | PE20090907A1 (enExample) |
| TW (1) | TW200909004A (enExample) |
| UY (1) | UY31235A1 (enExample) |
| WO (1) | WO2009013244A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100638936B1 (ko) * | 2005-03-31 | 2006-10-25 | 엘지전자 주식회사 | 건조기의 캐비닛 구조 |
| HUE067290T2 (hu) | 2009-02-26 | 2024-10-28 | Glaxo Group Ltd | 4-{(1 R)-2-[(6-{2-[(2,6-diklórbenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroxi-metil)fenolt tartalmazó gyógyszerkészítmények |
| EP2277799B8 (en) * | 2009-07-23 | 2012-04-11 | Airsec S.A.S. | Hydrated humidity control substance and process for its preparation |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| MD4117C1 (ro) * | 2010-07-30 | 2012-02-29 | Институт Химии Академии Наук Молдовы | Pudră cu capacitate hemostatică şi regenerativă (variante) şi procedeu de obţinere a acesteia |
| WO2012028663A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| EP3461474B1 (en) | 2010-08-31 | 2020-11-11 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| GB201113662D0 (en) * | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| ITMI20120092A1 (it) * | 2012-01-26 | 2013-07-27 | Micro Macinazione S A | Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia |
| US8545878B1 (en) | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
| WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| EP2934594B1 (en) | 2012-12-18 | 2019-09-04 | Almirall, S.A. | Cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities . |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| AR102305A1 (es) * | 2014-10-16 | 2017-02-15 | Teva Branded Pharmaceutical Products R&D Inc | Procedimiento para preparar formulación farmacéutica inhalable de polvo seco |
| KR101748796B1 (ko) * | 2015-09-30 | 2017-06-19 | 한미약품 주식회사 | 활성성분의 전달량이 향상된 흡입용 캡슐제 |
| CA169756S (en) | 2016-02-08 | 2017-09-01 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB201605102D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Mechanical connector for electronic vapour provision system |
| GB201605100D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision system |
| GB201605101D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| GB201605105D0 (en) | 2016-03-24 | 2016-05-11 | Nicoventures Holdings Ltd | Vapour provision apparatus |
| CN109476408A (zh) | 2016-07-22 | 2019-03-15 | 尼科创业控股有限公司 | 蒸汽供应装置外壳 |
| PL3833964T3 (pl) * | 2018-08-07 | 2023-09-04 | Norton (Waterford) Limited | Zastosowanie spektroskopii ramana do produkcji proszków do inhalacji |
| PL244452B1 (pl) * | 2020-08-24 | 2024-01-29 | Pulinno Spolka Z Ograniczona Odpowiedzialnoscia | Inhalator kapsułkowy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002822L (sv) * | 2000-08-04 | 2002-01-29 | Microdrug Ag | Elektropulver |
| EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| JP3691459B2 (ja) * | 2002-06-14 | 2005-09-07 | 久光メディカル株式会社 | 粉末状吸入剤組成物 |
| UA83813C2 (ru) * | 2002-12-20 | 2008-08-26 | Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг | Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола |
| GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
-
2008
- 2008-07-17 UY UY31235A patent/UY31235A1/es not_active Application Discontinuation
- 2008-07-17 PE PE2008001219A patent/PE20090907A1/es not_active Application Discontinuation
- 2008-07-18 EP EP08786245.4A patent/EP2182933B1/de active Active
- 2008-07-18 TW TW097127515A patent/TW200909004A/zh unknown
- 2008-07-18 JP JP2010517374A patent/JP2011509919A/ja active Pending
- 2008-07-18 US US12/670,001 patent/US20100189780A1/en not_active Abandoned
- 2008-07-18 WO PCT/EP2008/059465 patent/WO2009013244A1/de not_active Ceased
- 2008-07-18 CA CA2694479A patent/CA2694479C/en not_active Expired - Fee Related
- 2008-07-21 AR ARP080103160A patent/AR067639A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011509919A (ja) | 2011-03-31 |
| US20100189780A1 (en) | 2010-07-29 |
| EP2182933B1 (de) | 2016-09-07 |
| CA2694479A1 (en) | 2009-01-29 |
| WO2009013244A1 (de) | 2009-01-29 |
| TW200909004A (en) | 2009-03-01 |
| AR067639A1 (es) | 2009-10-21 |
| EP2182933A1 (de) | 2010-05-12 |
| UY31235A1 (es) | 2009-03-02 |
| PE20090907A1 (es) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2694479C (en) | Novel powderous medicaments comprising tiotropium and salmeterol and lactose as carrier | |
| US7462367B2 (en) | Anticholinergic powder formulations for inhalation | |
| AU2003288226B2 (en) | Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate | |
| US8197845B2 (en) | Encapsulated tiotropium containing powder formulation for inhalation | |
| US20040152720A1 (en) | Powdered medicaments containing a tiotropium salt and salmeterol xinafoate | |
| HRP20020437A2 (en) | Novel titropium-containing inhalation powder | |
| MXPA04009056A (es) | Bromuro de tiotropio cristalino micronizado. | |
| CN102164585B (zh) | 含有氨氯地平和比索洛尔的组合物 | |
| AU2003294714B2 (en) | Pulverulent formulation for inhalation containing tiotropium | |
| EP2515888B1 (en) | Dry powder formulation containing tiotropium for inhalation | |
| CA2531832C (en) | Powdery formulations for inhalation, containing a novel anticholinergic agent | |
| US8834931B2 (en) | Dry powder formulation containing tiotropium for inhalation | |
| TR201818680T4 (tr) | İnhalasyona yönelik formülasyonların hazırlanması için bir proses. | |
| JP2024178477A (ja) | カプセル剤 | |
| NZ540844A (en) | Pulverulent formulation for inhalation containing tiotropium | |
| HK1085918B (en) | Pulverulent formulation for inhalation containing tiotropium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130709 |
|
| MKLA | Lapsed |
Effective date: 20180718 |